IsomAb pockets £7.5M seed funding to spur development of arterial disease drug

2024-02-20

IsomAb is one step closer to bringing its peripheral artery disease (PAD) treatment to the clinic after closing a £7.5-million ($9.4 million) seed financing led by Broadview Ventures. Existing investor SCVC also participated in the round, as did MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures and part of the Midlands Engine Investment Fund.

The company’s lead candidate, ISM-001, is a preclinical isoform-specific monoclonal antibody (mAb) in development to treat PAD in patients with concomitant metabolic syndrome and type 2 diabetes.

ISM-001 is designed to enhance the body’s natural workaround when a buildup of fats block blood vessels, limiting blood flow to tissues and causing heart attack or stroke.

The production of new blood vessels to bypass the clogged ones relies on a balance of two VEGF-A isoforms: VEGF-A165a and VEGF-A165b. If levels of the latter are too high, the body is unable to create new vessels.

ISM-001 inhibits VEGF-A165b to rebalance the two isoforms and promote blood vessel production.

"IsomAb offers a fresh approach to the treatment of vascular disease. Although the initial focus will be on treating diabetics, research shows high levels of VEGF-A165b are also linked to increased risk of heart attack and stroke in non-diabetics, so it could have much wider applications,” Mercia Ventures partner Hannah Tapsell Chapman said.

Tuesday’s round will fund IsomAb through a clinical trial authorisation submission to UK regulators.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Isomab Ltd.